5 research outputs found
Genetic and Structural Characterization of a Thermo-Tolerant, Cold-Active, and Acidic Endo-β-1,4-glucanase from Antarctic Springtail, <i>Cryptopygus antarcticus</i>
The <i>CaCel</i> gene from Antarctic springtail <i>Cryptopygus
antarcticus</i> codes for a cellulase belonging
to the glycosyl hydrolase family 45 (GHF45). Phylogenetic, biochemical,
and structural analyses revealed that the <i>CaCel</i> gene
product (CaCel) is closely related to fungal GHF45 endo-β-1,4-glucanases.
The organization of five introns within the open reading frame of
the <i>CaCel</i> gene indicates its endogenous origin in
the genome of the species, which suggests the horizontal transfer
of the gene from fungi to the springtail. CaCel exhibited optimal
activity at pH 3.5, retained 80% of its activity at 0–10 °C,
and maintained a half-life of 4 h at 70 °C. Based on the structural
comparison between CaCel and a fungal homologue, we deduced the structural
basis for the unusual characteristics of CaCel. Under acidic conditions
at 50 °C, CaCel was effective to digest the green algae (<i>Ulva pertusa</i>), suggesting that it could be exploited for
biofuel production from seaweeds
Design, Synthesis, and in Vitro and in Vivo Evaluation of Ouabain Analogues as Potent and Selective Na,K-ATPase α4 Isoform Inhibitors for Male Contraception
Na,K-ATPase α4 is a testis-specific
plasma membrane Na<sup>+</sup> and K<sup>+</sup> transporter expressed
in sperm flagellum.
Deletion of Na,K-ATPase α4 in male mice results in complete
infertility, making it an attractive target for male contraception.
Na,K-ATPase α4 is characterized by a high affinity for the cardiac
glycoside ouabain. With the goal of discovering selective inhibitors
of the Na,K-ATPase α4 and of sperm function, ouabain derivatives
were modified at the glycone (C3) and the lactone (C17) domains. Ouabagenin
analogue <b>25</b>, carrying a benzyltriazole moiety at C17,
is a picomolar inhibitor of Na,K-ATPase α4, with an outstanding
α4 isoform selectivity profile. Moreover, compound <b>25</b> decreased sperm motility in vitro and in vivo and affected sperm
membrane potential, intracellular Ca<sup>2+</sup>, pH, and hypermotility.
These results proved that the new ouabagenin triazole analogue is
an effective and selective inhibitor of Na,K-ATPase α4 and sperm
function
Design, Synthesis, and in Vitro and in Vivo Evaluation of Ouabain Analogues as Potent and Selective Na,K-ATPase α4 Isoform Inhibitors for Male Contraception
Na,K-ATPase α4 is a testis-specific
plasma membrane Na<sup>+</sup> and K<sup>+</sup> transporter expressed
in sperm flagellum.
Deletion of Na,K-ATPase α4 in male mice results in complete
infertility, making it an attractive target for male contraception.
Na,K-ATPase α4 is characterized by a high affinity for the cardiac
glycoside ouabain. With the goal of discovering selective inhibitors
of the Na,K-ATPase α4 and of sperm function, ouabain derivatives
were modified at the glycone (C3) and the lactone (C17) domains. Ouabagenin
analogue <b>25</b>, carrying a benzyltriazole moiety at C17,
is a picomolar inhibitor of Na,K-ATPase α4, with an outstanding
α4 isoform selectivity profile. Moreover, compound <b>25</b> decreased sperm motility in vitro and in vivo and affected sperm
membrane potential, intracellular Ca<sup>2+</sup>, pH, and hypermotility.
These results proved that the new ouabagenin triazole analogue is
an effective and selective inhibitor of Na,K-ATPase α4 and sperm
function
Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors
Enzymes
of the ALDH1A subfamily of aldehyde dehydrogenases are
crucial in regulating retinoic acid (RA) signaling and have received
attention as potential drug targets. ALDH1A2 is the primary RA-synthesizing
enzyme in mammalian spermatogenesis and is therefore considered a
viable drug target for male contraceptive development. However, only
a small number of ALDH1A2 inhibitors have been reported, and information
on the structure of ALDH1A2 was limited to the NAD-liganded enzyme
void of substrate or inhibitors. Herein, we describe the mechanism
of action of structurally unrelated reversible and irreversible inhibitors
of human ALDH1A2 using direct binding studies and X-ray crystallography.
All inhibitors bind to the active sites of tetrameric ALDH1A2. Compound
WIN18,446 covalently reacts with the side chain of the catalytic residue
Cys320, resulting in a chiral adduct in (<i>R</i>) configuration.
The covalent adduct directly affects the neighboring NAD molecule,
which assumes a contracted conformation suboptimal for the dehydrogenase
reaction. The reversible inhibitors interact predominantly through
direct hydrogen bonding interactions with residues in the vicinity
of Cys320 without affecting NAD. Upon interaction with inhibitors,
a large flexible loop assumes regular structure, thereby shielding
the active site from solvent. The precise knowledge of the binding
modes provides a new framework for the rational design of novel inhibitors
of ALDH1A2 with improved potency and selectivity profiles
Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors
Enzymes
of the ALDH1A subfamily of aldehyde dehydrogenases are
crucial in regulating retinoic acid (RA) signaling and have received
attention as potential drug targets. ALDH1A2 is the primary RA-synthesizing
enzyme in mammalian spermatogenesis and is therefore considered a
viable drug target for male contraceptive development. However, only
a small number of ALDH1A2 inhibitors have been reported, and information
on the structure of ALDH1A2 was limited to the NAD-liganded enzyme
void of substrate or inhibitors. Herein, we describe the mechanism
of action of structurally unrelated reversible and irreversible inhibitors
of human ALDH1A2 using direct binding studies and X-ray crystallography.
All inhibitors bind to the active sites of tetrameric ALDH1A2. Compound
WIN18,446 covalently reacts with the side chain of the catalytic residue
Cys320, resulting in a chiral adduct in (<i>R</i>) configuration.
The covalent adduct directly affects the neighboring NAD molecule,
which assumes a contracted conformation suboptimal for the dehydrogenase
reaction. The reversible inhibitors interact predominantly through
direct hydrogen bonding interactions with residues in the vicinity
of Cys320 without affecting NAD. Upon interaction with inhibitors,
a large flexible loop assumes regular structure, thereby shielding
the active site from solvent. The precise knowledge of the binding
modes provides a new framework for the rational design of novel inhibitors
of ALDH1A2 with improved potency and selectivity profiles